Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Selexipag for Sale > 475086-01-2, Selexipag Huateng Pharma
475086-01-2, Selexipag    Huateng Pharma buy - large image1
475086-01-2, Selexipag    Huateng Pharma buy - image1

475086-01-2, Selexipag Huateng Pharma

Unit Price: Get Latest Price
CAS No.:

475086-01-2

Brand:

Huateng Pharma

Packaging:

upon inquiry

Price valid (until):

2022-11-02

Company Type:
Manufactory
Location:
China
Qualification:
Main Products:

fine chemicals,peg derivatives,pharma intermediates

  • Product Description

  • Seller Information

  • Description


      Product Detail  


    Selexipag is an orally available, highly selective, long-acting prostacyclin (IP) receptor agonist prodrug. It is a potential drug for the treatment of various vascular disorders such as pulmonary arterial hypertension and arteriosclerosis obliterans.

    ItemsSpecifications
    AppearanceWhite or of- white powder or crystlline power,odorless
    SolubilityVery soluble in N,N-Dimethylformamide,Soluble in methanol,Sparingly soluble inglacial acetic acid, Very slightly soluble inchloroform, Practically insoluble in water.
    Melting Point152°C~156°C
    ECHEMI Editorial Reference
    Selexipag and its active metabolite, the corresponding carboxylic acid, are nonprostanoid prostaglandin I2 (PGI-2) receptor agonists. The N-methylsulfonamide within selexipag is hydrolyzed to the corresponding carboxylic acid in vivo by hepatic microsomes at a rate which provides a slow-release pharmacological effect. The compound was originally discovered by Nippon Shinyaki and later licensed to Actelion for development. The drug was approved in 2015 and first launched for the oral treatment of pulmonary arterial hypertension (PAH) in the U.S. in 2016 to delay disease progression and reduce the risk of hospitalization.
    ChEBI: Selexipag is a member of the class of pyrazines that is N-(methanesulfonyl)-2-{4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetamide carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. An orphan drug used for the treatment of pulmonary arterial hypertension. It is a prodrug for ACT-333679 (the free carboxylic acid). It has a role as an orphan drug, a prostacyclin receptor agonist, a platelet aggregation inhibitor, a vasodilator agent and a prodrug. It is a monocarboxylic acid amide, an ether, a member of pyrazines, an aromatic amine, a tertiary amino compound and a N-sulfonylcarboxamide. It is functionally related to an ACT-333679.

    Basic Info
    Product Name:

    Selexipag

    Other Name:

    Selexipag;ACT-293987;NS-304(Selexipag);Selexipag API;2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylaMino]butoxy]-N-MethylsulfonylacetaMide;AcetaMide, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-Methylethyl)aMino]butoxy]-N- (Methylsulfonyl)-;Slipper;Selexipag intermediate 1

    CAS No.:

    475086-01-2

    Molecular Formula:

    C26H32N4O4S

    InChIKeys:

    QXWZQTURMXZVHJ-UHFFFAOYSA-N

    Molecular Weight:

    496.62

    Exact Mass:

    496.62

    Color/Form:

    Pale Yellow

    Characteristics
    Density:

    1.210±0.06 g/cm3(Predicted)

    Melting Point:

    134-138°C

    PKA:

    3.82±0.40(Predicted)

    Critical Temperature & Pressure:

    -20°C Freezer

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    fine chemicals,peg derivatives,pharma intermediates

    Location:

    Lugu Business Plaza E1,Yuelu District, Changsha City, Hunan Province

    Payment Terms:

    TT against copy of documents

    Average lead Time:

    30

    Total Annual Revenue:

    $25 million-$50 million

    Total Employees:

    301-500

    Year of Establishment:

    2013

    img

    Hunan Huateng Pharmaceutical Co., Ltd (hereinafter referred to as Huateng Pharma), founded in 2013, is a one-stop contract development and manufacturing organization (CDMO) to manufacture and supply researchers with PEG raw materials & PEG derivatives and products used across the pharmaceutical value chain including intermediates, excipients, APIs, and reagents. Today, Huateng Pharma employs more than 400 full time staff, and set up a professional and efficient R&D team with more than 10 national, provincial and municipal experts.

    At present, Huateng Pharma has established a 5000 square meters R&D center , equipped with nearly 100 sets of high-end analytical and testing instruments and automatic reaction equipment, such as 400 MHz NMR system, Agilent LC/MS, Waters HPLC, Agilent Intelligent GC system, etc., which can ensure fast and efficient completion of various customized orders from customers. 

    And we have a 34,000 square meter manufacturing site with advanced design concept of intelligent manufacturing, which can realize the integration of the production process and accomplish the complete transformation of lab scale - pilot plant - large-scale commercial production, with an annual capacity of more than 1 billion RMB.

    With our focus on operational excellence, and the integration of manufacturing operations with EHS, quality assurance, quality control, regulatory, supply chain management and project management, we are an ideal partner for global clinical development. Now, we have established cooperative relationships with more than 500 pharmaceutical companies at home and abroad.

  • Country Product Purchase Quantity Date Posted
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.